The Advances in Glioblastoma On-a-Chip for Therapy Approaches.
Arielly H AlvesMariana Penteado NucciJavier B MamaniNicole M E ValleEduarda F RibeiroGabriel N A RegoFernando Anselmo de OliveiraMatheus H TheinelRicardo S SantosLionel F GamarraPublished in: Cancers (2022)
This systematic review aimed to verify the use of microfluidic devices in the process of implementing and evaluating the effectiveness of therapeutic approaches in glioblastoma on-a-chip, providing a broad view of advances to date in the use of this technology and their perspectives. We searched studies with the variations of the keywords "Glioblastoma", "microfluidic devices", "organ-on-a-chip" and "therapy" of the last ten years in PubMed and Scopus databases. Of 446 articles identified, only 22 articles were selected for analysis according to the inclusion and exclusion criteria. The microfluidic devices were mainly produced by soft lithography technology, using the PDMS material (72%). In the microenvironment, the main extracellular matrix used was collagen type I. Most studies used U87-MG glioblastoma cells from humans and 31.8% were co-cultivated with HUVEC, hCMEC/D3, and astrocytes. Chemotherapy was the majority of therapeutic approaches, assessing mainly the cellular viability and proliferation. Furthermore, some alternative therapies were reported in a few studies (22.6%). This study identified a diversity of glioblastoma on-a-chip to assess therapeutic approaches, often using intermediate levels of complexity. The most advanced level implemented the intersection between different biological systems (liver-brain or intestine-liver-brain), BBB model, allowing in vitro studies with greater human genetic similarity, reproducibility, and low cost, in a highly customizable platform.
Keyphrases
- high throughput
- circulating tumor cells
- systematic review
- extracellular matrix
- case control
- low cost
- single cell
- endothelial cells
- stem cells
- resting state
- blood brain barrier
- gene expression
- squamous cell carcinoma
- dna methylation
- signaling pathway
- genome wide
- bone marrow
- multiple sclerosis
- tissue engineering
- replacement therapy